With the most recent addition to our board two years ago and just recently was named as chairman of the board of Teva pharmaceuticals and he has a tremendous background in medicine that he brings to bare at the board. I myself came from Johnson and Johnson where I spent fifteen years most recently. I ran their cancer diagnostics business which I took from four million dollars in sales to thirty million dollars in sales in three years and that is what we are looking to do here at Rosetta Genomics.
Our most recent hire to the management team is Doug Sites. Doug brings a breadth of expertise in all the areas that we could have hoped for. Oncology, Micro RNAs and very important for us thyroid because we are about to launch our thyroid test in about six months.
Doctor Robert Wassman was brought in a little over two years ago to really rejuvenate the pipeline building effort which we have done and you will see that in a minute.
So we have been at this for 14 years and we are and we believe we are the leaders in the Micro RNA biomarker space to the mass of hundreds of RND menus in discovering experimenting and developing complex Micron RNA signatures. We have moved the field forward by demonstrating the relevance of Micro RNAs in oncology and in places outside of oncology like cardiovascular disease. And one of the things that we have spent a lot of time and we still spend time on it is optimizing the development engine.
Micro RNAs ,the good thing about Micro RNAs for us is that they are difficult to work with, that’s right they are difficult to work with, so we have a mass a ton of experience on how to work with these tricky molecules and we continue to optimize our development platform, so we can get better and better and more accurate tests and you will see some of that accuracy in the descriptions of these test as we move forward but at the heart of everything we do really of the mass right, so it’s great to generate signals of Micro RNAs from different sample types but you have take those pieces of information and turn them into something actionable and the company was founded on a bioinformatics back bone and so we have cutting edge expertise’s in this fix that allows us to bring to the market valuable information for clinications by taking these pieces of information and turning them into a diagnoses and the proofs and the putting so we have completed the development of six Mircro RNA based assay. There have been only seven launched today so there is only one other Micron RNA based assay that’s has ever been launched outside Rosetta.
So we picked cancer as our first area to play in and that is because there has been a ton of work to demonstrate the relevance of Micro RNAs in cancer. I won’t get through all the technical details on this slide but it is clear that Micro RNAs has played key roles in different aspects of cancer, different ways that cancer is caused and so that’s why cancer was the number one area that we selected. So we have launched our cancer testing services. We have four tests on the market but we will focus on the cancer origin test that’s our lead test. That’s the one that our sales reps primarily detail to both oncologists and pathologists. So we will talk about that so what if that test aimed to solve, to solve the issues that the doctors face actually more commonly then people might think. A patient who has cancer presents with, a medic static lead in other words, it is spread from where it initially started from the primary side and for some reason they cannot determine where the cancer started, knowing where the cancer starts is critical to determining how to treat people.
